HLB Group Chairman Kim Tae-han says liver cancer drug approval could come as early as this year
Predicted impact: Medium· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
Chairman expects FDA approval this year on liver cancer drug; a key catalyst but repeated statements in last 14 days.